# Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases

> **NCT05769010** · PHASE2 · RECRUITING · sponsor: **Henan Cancer Hospital** · enrollment: 150 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** SHR-A1811
- **DRUG:** Pyrotinib
- **DRUG:** Bevacizumab
- **DRUG:** Adebelizumab

## Key facts

- **NCT ID:** NCT05769010
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-31
- **Primary completion:** 2028-12-30
- **Final completion:** 2029-06-30
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05769010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05769010, "Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05769010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*